MX2021007426A - Compuestos de imidazopiridazina e imidazopiridina como inhibidores de cinasa-2 de tipo receptor de activina. - Google Patents

Compuestos de imidazopiridazina e imidazopiridina como inhibidores de cinasa-2 de tipo receptor de activina.

Info

Publication number
MX2021007426A
MX2021007426A MX2021007426A MX2021007426A MX2021007426A MX 2021007426 A MX2021007426 A MX 2021007426A MX 2021007426 A MX2021007426 A MX 2021007426A MX 2021007426 A MX2021007426 A MX 2021007426A MX 2021007426 A MX2021007426 A MX 2021007426A
Authority
MX
Mexico
Prior art keywords
compounds
imidazopyridazine
kinase
inhibitors
activin receptor
Prior art date
Application number
MX2021007426A
Other languages
English (en)
Spanish (es)
Inventor
Song Mei
Jun Pan
Liangxing Wu
Chunhong He
Wenqing Yao
Jeremy Roach
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MX2021007426A publication Critical patent/MX2021007426A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2021007426A 2018-12-20 2019-12-19 Compuestos de imidazopiridazina e imidazopiridina como inhibidores de cinasa-2 de tipo receptor de activina. MX2021007426A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782994P 2018-12-20 2018-12-20
US201962935891P 2019-11-15 2019-11-15
PCT/US2019/067403 WO2020132197A1 (en) 2018-12-20 2019-12-19 Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Publications (1)

Publication Number Publication Date
MX2021007426A true MX2021007426A (es) 2021-09-08

Family

ID=69467674

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007426A MX2021007426A (es) 2018-12-20 2019-12-19 Compuestos de imidazopiridazina e imidazopiridina como inhibidores de cinasa-2 de tipo receptor de activina.

Country Status (20)

Country Link
US (3) US11459329B2 (cg-RX-API-DMAC7.html)
EP (1) EP3898627A1 (cg-RX-API-DMAC7.html)
JP (2) JP7414827B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210116488A (cg-RX-API-DMAC7.html)
CN (2) CN114787160B (cg-RX-API-DMAC7.html)
AU (1) AU2019401649B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011948A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124088A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001656A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021008117A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210336A (cg-RX-API-DMAC7.html)
EC (1) ECSP21044843A (cg-RX-API-DMAC7.html)
IL (2) IL318278A (cg-RX-API-DMAC7.html)
MA (1) MA54551A (cg-RX-API-DMAC7.html)
MX (1) MX2021007426A (cg-RX-API-DMAC7.html)
PE (1) PE20220277A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551446A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106582YA (cg-RX-API-DMAC7.html)
TW (2) TW202504901A (cg-RX-API-DMAC7.html)
WO (1) WO2020132197A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7414827B2 (ja) * 2018-12-20 2024-01-16 インサイト・コーポレイション アクチビン受容体様キナーゼ-2の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
US11840546B2 (en) * 2020-06-12 2023-12-12 Incyte Corporation Imidazopyridazine compounds and uses thereof
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
CN118119619A (zh) * 2021-10-18 2024-05-31 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途
KR102961396B1 (ko) 2022-11-28 2026-05-08 계명대학교 산학협력단 신규한 pim 키나아제 억제제 및 이의 용도

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
PT1283839E (pt) 2000-05-26 2005-08-31 Schering Corp Antagonistas do receptor a2a da adenosina
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
EP1615931A1 (en) 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines and methods of making and using the same
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
DE602005023763D1 (de) 2004-11-04 2010-11-04 Vertex Pharma Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
GEP20125658B (en) * 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
HUP0700395A2 (en) 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
KR101150581B1 (ko) * 2007-07-26 2012-06-11 노파르티스 아게 유기 화합물
EA201000615A1 (ru) * 2007-10-17 2010-12-30 Новартис Аг Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
JP2012533545A (ja) 2009-07-14 2012-12-27 ベス・イスラエル・ディーコネス・メディカル・センター,インコーポレイテッド 肝臓の増殖を増大させる方法
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
JP5926727B2 (ja) 2010-07-28 2016-05-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換イミダゾ[1,2−b]ピリダジン
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
US20140171434A1 (en) 2011-01-11 2014-06-19 Bayer Pharma Aktiengessellschaft Substituted imidazopyridines and imidazopyridazines and the use thereof
JP6430383B2 (ja) 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーVanderbilt University 選択的bmp阻害剤としての縮合複素環化合物
MX2015005375A (es) 2012-11-07 2015-07-21 Hoffmann La Roche Compuestos de triazolo.
JP6542192B2 (ja) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. Bmp阻害剤およびその使用方法
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (en) 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
PL3500571T3 (pl) 2016-08-17 2021-06-28 Children's Hospital Medical Center Związki imidazo[1,2-a]pirydynowe, kompozycje je zawierające, sposoby leczenia chorób z ich wykorzystaniem oraz sposoby ich wytwarzania
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018053126A1 (en) * 2016-09-14 2018-03-22 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
US11371744B2 (en) 2016-09-15 2022-06-28 Awi Licensing Llc Ceiling system with air movement
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
EP4223369A1 (en) 2016-12-22 2023-08-09 Incyte Corporation Immunomodulator compounds and methods of use
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
US20200054643A1 (en) 2017-01-18 2020-02-20 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
WO2018165569A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Therapeutic compounds and methods
KR20190129851A (ko) 2017-03-16 2019-11-20 지앙수 헨그루이 메디슨 컴퍼니 리미티드 헤테로아릴[4,3-c]피리미딘-5-아민 유도체, 이의 제조 방법 및 이의 의학적 용도
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
MA50440A (fr) 2017-10-24 2020-09-02 Bayer Ag Imidazopyridinamides substituées et leur utilisation
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
JP7414827B2 (ja) 2018-12-20 2024-01-16 インサイト・コーポレイション アクチビン受容体様キナーゼ-2の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物
US11840546B2 (en) 2020-06-12 2023-12-12 Incyte Corporation Imidazopyridazine compounds and uses thereof

Also Published As

Publication number Publication date
JP2022514650A (ja) 2022-02-14
SG11202106582YA (en) 2021-07-29
JP2024045155A (ja) 2024-04-02
TWI852968B (zh) 2024-08-21
CR20210336A (es) 2021-12-06
CN120208959A (zh) 2025-06-27
TW202039502A (zh) 2020-11-01
IL284139A (en) 2021-08-31
PE20220277A1 (es) 2022-02-25
JP7723068B2 (ja) 2025-08-13
AU2019401649B2 (en) 2025-08-28
CN114787160A (zh) 2022-07-22
AU2019401649A1 (en) 2021-07-08
CO2021008117A2 (es) 2021-09-20
EP3898627A1 (en) 2021-10-27
CA3124088A1 (en) 2020-06-25
CL2021001656A1 (es) 2021-12-17
US11459329B2 (en) 2022-10-04
IL284139B1 (en) 2025-02-01
US20240309008A1 (en) 2024-09-19
ECSP21044843A (es) 2021-09-30
JP7414827B2 (ja) 2024-01-16
US20200199131A1 (en) 2020-06-25
MA54551A (fr) 2021-10-27
US20220315595A1 (en) 2022-10-06
PH12021551446A1 (en) 2021-12-06
BR112021011948A2 (pt) 2021-09-08
TW202504901A (zh) 2025-02-01
US12030889B2 (en) 2024-07-09
IL318278A (en) 2025-03-01
WO2020132197A1 (en) 2020-06-25
KR20210116488A (ko) 2021-09-27
IL284139B2 (en) 2025-06-01
CN114787160B (zh) 2025-03-25

Similar Documents

Publication Publication Date Title
ECSP24009853A (es) Compuestos tricíclicos como inhibidores de kras
CO2021008117A2 (es) Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
ECSP24035717A (es) Compuestos de quinolina como inhibidores de kras
ECSP20060827A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
MX2023004518A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
MX2018012609A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
PE20151594A1 (es) Inhibidores de indolamina 2-3 dioxigenasa
CL2022000457A1 (es) Triazolopirimidinas como inhibidores de a2a/a2b.
ECSP17021897A (es) Compuestos y composiciones como inhibidores de quinasa raf
MX2015015738A (es) Derivados del bipirazol como inhibidores de janus cinasa (jak).
MX2021009142A (es) Inhibidores topicos de fosfoinositol 3-cinasas.
CO2022017969A2 (es) Compuestos de imidazopiridazina con actividad como inhibidores de alk2
AR117459A1 (es) Imidazopiridina y compuestos de imidazopiridazina y usos de los mismos
AR126389A1 (es) Compuestos tricíclicos como inhibidores de kras
EA202191738A1 (ru) Соединения имидазопиридазина и имидазопиридина и их применение
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores
CU20100038A7 (es) 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos